QTEX Volume Jumps 9.6x on Patent-Pending Quantum Carbon Breakthrough
QTEX volume surged 9.6x its 20-day average after a quantum-tech patent announcement, but the unclassified small-cap posts -570.7% ROE amid a calm VIX-14.9 macro backdrop.
signal:QTEX:2026-08-19 QTEX Volume Jumps 9.6x on Patent-Pending Quantum Carbon Breakthrough
Shares of QTREX Quantum (QTEX) saw volume surge to 9.6x the 20-day average on August 19, the same day the company announced a patent-pending technology it says achieved the first direct conversion of 3D-printed dielectric material into electrically conductive, graphene-like carbon — a development that, combined with a July 31 announcement that its printed coaxial quantum interconnect platform surpassed RF performance requirements, positions QTEX as a name to watch for continued speculative interest tied to its quantum-connectivity technology roadmap rather than any near-term earnings catalyst.
The move also comes alongside a quarterly EPS surprise of +42.5% (actual -0.17 vs. expected -0.2958 for the period ended 2023-12-31), a reminder that this is still a loss-making company where sentiment around technology headlines, not profitability, is currently driving price action.
Key Facts
| Stock name | QTEX |
|---|---|
| Ticker | QTEX |
| Market | NASDAQ |
| Sector | Unclassified |
| Volume (x average) | 9.6x |
| Signal price | $1.12 |
QTREX Quantum Ltd. develops proprietary life support technology for treating acute respiratory failure alongside advanced connectivity solutions for the quantum computing industry, operating out of Israel and the USA. Its medical line includes the INSPIRA ART100 life support system, used in cardiopulmonary bypass procedures of six hours or less, and the HYLA blood sensor for real-time blood parameter analysis. On the connectivity side, the company builds cryogenic interconnect systems and is developing a monolithic interconnect architecture that integrates conductors, RF dielectric, and shielding into a single printed structure.
Recent Analyst Coverage
External analyst opinions (not investment advice): (2026-08-01)
| Strong Buy | 2 |
|---|---|
| Buy | 4 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
Peer Companies
ABOU.TA, EPIT.TA, PLSM.TA, MRHL.TA, IDNT.TA
Risk Factors
QTEX carries the profile of an early-stage, cash-burning technology company: return on equity of -570.7% and negative EV/EBITDA of -2.7x point to a business still far from sustainable profitability, and its dual focus on medical life-support devices and quantum interconnects — an unclassified, hard-to-benchmark industry combination — makes it difficult to value against direct peers. Patent-pending status is not the same as a proven, revenue-generating product, and a headline-driven volume spike like this one can reverse sharply once trading interest fades.
On the macro side, the backdrop is currently calm — VIX sits at 14.9 and the U.S. high-yield credit spread is flat around 2.75 percentage points — which has generally supported risk appetite in small, speculative names. However, the 10-year Treasury yield is holding flat near 4.65% while the dollar index (DXY) has fallen 2.3% over the past month; a reversal in either the low-volatility regime or the softer-dollar trend could quickly reduce the risk tolerance that names like QTEX depend on.
Recent Disclosures
No disclosures in the past 30 days.
Recent News
- 2026-08-19 What's going on in today's session
- 2026-08-19 QTREX Quantum Announces A Patent-Pending Technology Achieved First Direct Conversion Of 3D-Printed Dielectric Material Into Electrically Conductive, Graphene-Like Carbon
- 2026-07-31 QTREX Quantum Announces Its Printed Coaxial Quantum Interconnect Platform Surpasses RF Performance Requirements
Pre-Trade Checklist
| Business & competitive edge understood | ✅ Company profile summarized above |
|---|---|
| Leading sector | ⚠️ Not flagged as a leading sector |
| Good news already priced in? | ⚠️ Insufficient valuation data to judge |
| Stop-loss / take-profit set | ✅ Stop-loss -10% / first take-profit +20% set in advance |
| Exit plan if wrong | ✅ 10% trailing stop from peak; setup auto-invalidated on a break below key support |
Trade Levels
| Signal price | $1.12 |
|---|---|
| Stop-loss | $1.01 (-10% from signal price) |
| First take-profit | $1.34 (+20% from signal price) |
| Trailing stop | 10% from peak |
| Invalidation | Close back below key support ($1.10) |
With shares trading around the $1.12 signal level, this remains a watchlist setup rather than a conviction call: the reference framework points to a first target near $1.34 (+20%) with a protective stop at $1.01 (-10%), while a close back below $1.10 would undercut the thesis behind this move. Investors tracking QTEX should watch whether the patent-pending technology translates into further news flow or partnership traction, as that — more than the current volume spike alone — will determine whether the setup holds.